Company Overview and News

 
LeEco founder Jia Yueting receives financial lifeline from mystery Hong Kong investor

2018-04-19 scmp
Struggling Chinese businessman Jia Yueting, who is on a nationwide blacklist of debt defaulters, has received a funding lifeline from a mysterious Hong Kong investor, Caixin reported.

 
Hong Kong property firm Chinese Estates increases stake in China Evergrande

2018-04-04 scmp
Analysts say the Hong Kong firm is looking to rebuild its portfolio after a series of asset sales last year

 
Top 50 Real Estate Stocks: Yields To 18.5%; Gains To 45.25% By March 2019

2018-03-06 seekingalpha
GEO Group led by net gains and estimated price growth as Chinese Estates led by yield. Top ten gainers, GOV, SLD, AJX, SNH, CHMI, CHMI, GOOD, WSR, CIO, SIR, &.

 
79 High Yield 10%+ Dividend Leaders Could Deliver Up To 39% By March 2019

2018-02-28 seekingalpha
79 U.S. stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 2/26/18. Yields above 12.2% narrowed the list to 30 for comparison.

 
Chinese Estates profit tumbles 42pc as rentals fall after former chairman’s asset sell-offs

2018-02-22 scmp
Chinese Estates Holdings, the Hong Kong property developer, has reported a 42 per cent plunge in full-year net profit for 2017 following a series of asset disposals, after a major share restructuring prompted by former chairman Joseph Lau Luen-hung’s recent failing health.

1
Top 50 Real Estate Stocks Fetch Up To 19.7% Yields And 75.29% Net Gains To January 2019

2018-01-31 seekingalpha
Colony led by net-gains and estimated price-growth as Chinese Estates led by yield. Top ten gainers, DX, STWD, MFA, MTGE, CHMI, WRI, EARN, SIR, GMRE, & CLNS ranged 20.7%-72.29%.

 
Top 50 Real Estate Stocks Fetch Up To 19.7% Yields & 75.29% Net Gains To January 2019

2018-01-31 seekingalpha
Colony led by net-gains and estimated price-growth as Chinese Estates led by yield. Top ten gainers, DX, STWD, MFA, MTGE, CHMI, WRI, EARN, SIR, GMRE, & CLNS ranged 20.7%-72.29%.

1
85 10%+ Yield Dividend Stocks: Stonemore, Uniti, American Shipping & China Dongxiang Top Broker Target Gains To February 2019

2018-01-29 seekingalpha
85 U.S. stocks displayed 10%+ forward yield, $2+ prices, and $100M+ market caps as of 1/26/18. Yields above 12.60% narrowed the list to 30 for comparison.

 
Shorting China's Dark Horses - Bloomberg Gadfly

2017-11-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

1
Li Ka-shing sells The Center in US$5.15 billion record deal to trim his flagship’s Hong Kong assets

2017-11-01 scmp
The buyer is a consortium of Hong Kong investors and Chinese buyers led by Beijing-based China Energy Reserve & Chemicals Group, sources said.

1
Deals of the day-Mergers and acquisitions

2017-10-04 reuters
Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Wednesday:

 
Mandarin Oriental pulls sale of Hong Kong’s Excelsior Hotel after bids failed to meet expectations

2017-09-27 scmp
Mandarin Oriental International has decided to withdraw the disposal of its iconic hotel Excelsior in Causeway Bay, after the bidders failed to submit a proposal that met expectations and transaction requirements.

 
China's Curbs, Debt Woes Bring Developers Crashing Back to Earth - Bloomberg

2017-09-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Mandarin Oriental shares surge 21pc as it receives potential buyers for Excelsior Hotel

2017-09-15 scmp
Shares of Mandarin Oriental International surged more than 20 per cent on Friday after the company announced it has received proposals from potential purchasers to acquire its iconic Excelsior Hotel in Causeway Bay.

 
Chinese Estates issues first-half profit warning, as rental income falls

2017-08-11 scmp
Hong Kong landlord expects net profit to drop between 8pc and 18pc, with revenue to slump between 60pc and 70pc

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...